Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 02:50PM GMT
Release Date Price: $117.1 (+6.80%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Neurocrine Biosciences with CEO, Kevin Gorman; and CFO, Matthew Abernethy. Welcome, Kevin and Matt.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you very much.

Matthew C. Abernethy
Neurocrine Biosciences, Inc. - CFO

Thank you.

Jeff Hung;Kevin C. Gorman
Morgan Stanley, Research Division - Equity Analyst;Neurocrine Biosciences,

So for those who may not be familiar with Neurocrine, can you provide a brief introduction?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot